precisionmedicineonline5 小时
CHMP Recommends Approval of J&J's Subcutaneous Rybrevant for Certain NSCLC Patients in Europe
The committee recommended the new formulation in two EGFR-mutated advanced NSCLC settings, for which intravenous Rybrevant is already available.
precisionmedicineonline7 小时
UniQure Testing Higher Gene Therapy Dose in Phase I/II Fabry Disease Trial
The firm will begin testing a second dose cohort with AMT-191 after receiving a positive recommendation from a data monitoring committee.